Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lymphoseek in Elective Neck Dissection for HNSCC
NCT00911326Phase 3Terminated
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- May 2009
- Primary completion
- Aug 2013
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of technetium tc 99m tilmanocept in head and neck squamous cell carcinoma (HNSCC), sponsored by Navidea Biopharmaceuticals, Inc.. Started May 2009; status: terminated.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00911326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00911326.